论文部分内容阅读
本文按FAB标准将43例MDS患者分成两大组:(1)难治性贫血不伴原始细胞过多(RAWEB,原始细胞<5%)29例;(2)难治性贫血伴有原始细胞过多(RAEB,原始细胞≥5%)14例。RAWEB组:1例骨髓无细胞系列增生异常(NLD),6例有单项细胞系列增生异常(SLD),10例有两项细胞系列增生异常(BLD),12例有3项细胞系列增生异常(TLD);所有RAEB组均为TLD。RAWEB组9例(31%)死亡,RAEB组9例(64%)死亡。死亡病例中RAWEB有3例(占死亡数33%),RAEB9例(占死亡数100%)最后死于急非淋白血病(ANLL)或骨髓纤维化(BMF)。
In this paper, 43 patients with MDS were divided into two groups according to FAB criteria: (1) refractory anemia without primordial cells (RAWEB, primitive cells <5%) in 29 cases; (2) refractory anemia accompanied by primitive cells Too much (RAEB, primitive cells ≥ 5%) in 14 cases. In the RAWEB group, there were 1 case of myeloid atrophic myeloid leukemia (NLD), 6 cases of single cell line dysplasia (SLD), 10 cases of two cell line hyperplasia (BLD) and 12 cases of 3 cell line dysplasia TLD); all RAEB groups are TLDs. 9 (31%) died in the RAWEB group and 9 (64%) died in the RAEB group. Three of the deaths were RAWEB (33% of deaths), and 9 of RAEB (100% of deaths) eventually died of acute leukemia (ANLL) or myelofibrosis (BMF).